Home-made PD-1 therapy! Baiji Shenzhou Baizean ® (for Reilly zhu single resistance) treatment of non-small cell lung cancer Phase 3 clinical success!
New medicine for rare diseases! C3 inhibitor pegcetacoplan received FDA priority review: Phase 3 efficacy beats heavyweight C5 inhibitor Soliris
Health Care Commission: 3 new confirmed cases, including 1 new case in the local area
Today's 9 generics reviews: 6 for the first 3 injections
NEJM: Prevention of 1/3 of major cardiovascular events Autumn daffodils to treat chronic coronary heart disease added evidence
First-line immunotherapy for lung cancer! Anti-PD-1 therapy Libtayo enters US-Eu review: Treatment